STAGEZERO Aktie

 

  TORONTO, ON  - TheNewswire - May 13, 2025 - StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), and ElevationMD (“ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer. StageZero is an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and AVRT, an oncologist-led  metabolic screening and treatment protocol for detecting the early warning signs of cancer and chronic disease, together with ElevationMD today announced they are introducing state of the art early cancer screening to ElevationMD's patients in British Columbia. ElevationMD is a physician-led innovative medical clinic.  ElevationMD's goal is to combine, organize a...

TORONTO – TheNewswire - May 7, 2025 - StageZero Life Sciences, Ltd. (the “Company” or “StageZero”) (TSX: SZLS) announces that the Ontario Securities Commission (“OSC“) issued an order dated April 30. 2025 (the “Partial Revocation Order”) partially revoking the failure-to-file cease trade order issued against the Company on April 9, 2024 (the “FFCTO“) for failing to file certain outstanding continuous disclosure documents (collectively, the “Documents”) within the timeframes prescribed by applicable securities laws. The Partial Revocation Order permits the Company to conduct a financing on a private placement basis (the “Proposed Financing”). The FFCTO continues to apply in all other respects. The Partial Revocation Order permits the Company to complete a private placement (the “Private Placement”) of either, or a combination of:  (i). up to $2,000,000 of non-convertible notes bearing an interest rate of between 12% to 14% per annum (a Debt Offering), or (ii) a convertibl...

  TORONTO, ON – TheNewswire - December 16, 2024 - StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its third quarter financial results for the three and nine months ended September 30, 2024, and provided an update on its business operations. “The third quarter focused on the revitalization of our corporate offerings and integration of changes that were made during Q2 and Q3.” said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences.  “Key now, is to launch into our strategic partnerships to fuel the uptake of our Aristotle test and increase revenues” he further added.   Operational Update The Company has been under a failure to file cease tra...

  TORONTO, ON – TheNewswire - October 1, 2024 - StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its second quarter financial results for the three and six months ended June 30, 2024, and will provide an update on its business operations.   “This first half of 2024 has been a very different period for us and one in which we have used it to the best advantage we can - focussing on operational and strategic changes to bring the Company into a more efficient mode.  Changes such as the ones the Company has recently made invariably disrupt operations but we are pleased that we have already started seeing the results of these changes, particularly with where we want...

TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene......

TORONTO, ON / ACCESSWIRE / July 3, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene......